Inclusion body myositis with granuloma formation in muscle tissue

	Sakai Kenji, Ikeda Yoshihisa, Ishida Chiho, Matsumoto Yasuko, Ono Kenjiro, Iwasa Kazuo, Yamada Masahito
journal or publication title	Neuromuscular Disorders
volume	25
number	9
page range	706-712
year	2015-09-01
URL	http://hdl.handle.net/2297/43403

Inclusion body myositis with granuloma formation in muscle tissue

Kenji Sakai [a], Yoshihisa Ikeda [a,b], Chiho Ishida [a,b], Yasuko Matsumoto [a,c], Kenjiro Ono [a], Kazuo Iwasa [a], Masahito Yamada [a]

[a] Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
[b] Department of Neurology, National Hospital Organization Iou Hospital, Kanazawa, Japan
[c] Department of Neurology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

Correspondence to: Dr Kenji Sakai
Department of Neurology and Neurobiology of Ageing, Kanazawa University
Graduate School of Medical Science
13-1 Takara-machi, Kanazawa 920-8640, Japan
Fax: +81-76-234-4253
Phone: +81-76-265-2292
E-mail: ksakai@med.kanazawa-u.ac.jp

Conflicts of interest

None

Abstract

Inclusion body myositis is a form of inflammatory myopathy. We identified 4 cases of

inclusion body myositis showing granuloma formation in muscle tissue and aimed to

assess the features of this atypical form of the inclusion body myositis.

We retrospectively reviewed consecutive patients who satisfied European

Neuromuscular Centre IBM Research Diagnostic Criteria 2011. Then, we assessed

clinical profiles and pathological findings in patients with inclusion body myositis

with granuloma and compared these findings with those of typical inclusion body

myositis without granuloma.

We identified 15 patients with inclusion body myositis. Four patients

showed granuloma formation in muscle tissue in addition to typical pathological

features of inclusion body myositis. Granulomas comprised a mixture of

inflammatory cells, such as macrophages, epithelioid histiocytic cells, and

lymphocytes. One patient was found to have mediastinal granulomatous

lymphadenopathy; however, the evidence in other patients was insufficient for a

diagnosis of systemic sarcoidosis. There were no significant differences between

groups with and without granuloma regarding clinical manifestations, laboratory

findings, response to immunomodulating therapies, or myopathological profiles.

We established a new form of inclusion body myositis showing granuloma formation in muscle tissue. Inclusion body myositis and granuloma formation could have identical pathomechanisms concerning dysregulation of autophagy.

(198 words)

Key words: inclusion body myositis; granuloma; rimmed vacuole; autophagy

Abbreviations

COX, cytochrome C oxidase; ENMC, the European Neuromuscular Centre; GM, granulomatous myositis; HE, hematoxylin and eosin; HLA, human leukocyte antigen; IBM, inclusion body myositis; IVIg, intravenous immunoglobulin; TLR, toll-like receptor

1. Introduction

Inclusion body myositis (IBM) is a type of inflammatory myopathy characterized by T lymphocyte infiltration around muscle fibers and the presence of rimmed vacuoles [1]. In comparison to other types of inflammatory myopathy, including polymyositis and dermatomyositis, patients with IBM demonstrate an unfavorable response to immunosuppressive therapy [1]. The pathomechanisms of IBM remain uncertain. Inflammatory processes and degenerative mechanisms are both responsible for the development of this muscular disorder.

Granulomas are pathological structures comprising giant cells, macrophage-like epithelioid cells, and lymphocytes. The most common condition associated with non-caseating granuloma formation in muscle tissues is sarcoidosis

followed by foreign-body reactions and infectious conditions; however,

granulomatous myositis (GM) is a type of inflammatory myopathy containing

granulomas without any evidence of systemic sarcoidosis despite intensive clinical

investigations [2].

Although there are several reported cases that presented features of both

IBM and sarcoidosis [3-5], the relationship between IBM and granuloma formation

remains to be clarified. In this study, we identified 4 patients with IBM showing

granuloma formation in muscle tissues. Somewhat surprisingly, granulomas were

confined to skeletal muscle in 3 patients. This study aimed to elucidate the features of

IBM with granuloma by comparing these features with the clinical and

histopathological features of patients with typical IBM.

2. Materials and methods

2.1 Patients

We retrospectively reviewed consecutive patients who underwent an open muscle

biopsy in our hospital and were referred to our department for pathological diagnosis

of muscle biopsies between 2003 and 2013. We selected IBM patients who satisfied

the European Neuromuscular Centre (ENMC) IBM Research Diagnostic Criteria 2011

[6], and applied the classification as follows: clinicopathologically defined IBM,

clinically defined IBM, and probable IBM.

Medical records were retrospectively reviewed for age at diagnosis, sex,

sites of initial weakness, and duration from onset to diagnosis. The following

laboratory features determined at the time of diagnosis were obtained: the levels of

serum creatine kinase, lactate dehydrogenase, aldolase, and myoglobin; levels of

plasma C-reactive protein; and erythrocyte sedimentation rate. In addition, we

examined the presence of serum autoantibodies suggestive of other collagen disorders,

hepatitis B antigens, and hepatitis C antibodies.

Special attention was paid to patients showing granulomas in muscle to

exclude the possibility of systemic sarcoidosis. A clinical diagnosis of sarcoidosis

could be made on the basis of clinical, laboratory, and radiological features in addition

to evidence of non-caseating granulomas in tissues. Moreover, it is essential to

exclude alternative diseases [7]. In terms of clinical presentation, pulmonary

symptoms and abnormal chest radiographs including bilateral hilar lymphadenopathy

are common; however, rarely patients may show only extrapulmonary manifestations

[7.] Granulomatous myositis is a type of myositis characterized by granuloma

formation in muscle tissue, variable response to immunosuppressive therapies, and no

evidence of systemic sarcoidosis [2]. Although it is uncertain whether GM is a limited

form of systemic sarcoidosis, not all patients with GM develop symptoms of

sarcoidosis [8]. To avoid making a diagnosis of sarcoidosis, the patients with IBM

showing granuloma underwent intensive examinations, which included

ophthalmological examinations, chest radiographs, and whole body examinations.

Other disorders which might cause granulomatous myositis, such as tuberculosis

infection, lymphoma, intestinal inflammatory disease, myasthenia gravis,

foreign-body reaction, cryofibrinogenemia, and primary biliary cirrhosis [2], were

excluded carefully by performing radiological and clinical investigations.

Most patients received immunosuppressive therapy as follows:

corticosteroids (prednisone and methylpredonisolone), immunosuppressive drugs, and

intravenous immunoglobulin (IVIg). The results of these treatments were examined

by retrospectively reviewing the medical records.

Written informed consent to participate in this study was obtained from the

patients. The study protocol was approved by the medical ethics committee of

Kanazawa University.

2.2 Pathological examinations

Muscle biopsies were performed in all patients. All samples were obtained by open

biopsies and divided into several blocks. Some specimens were immediately frozen in

isopentane cooled with liquid nitrogen and stored at -80˚C until the experiments.

Serial 6-µm-thick cryostat sections were cut and stained with hematoxylin and eosin

(HE), modified Gomori trichrome, NADH-tetrazolium, Congo Red, and cytochrome

C oxidase (COX). The remaining samples were fixed with 10% buffered formalin.

Pathological examinations were also performed on 5-µm-thick sections of paraffin

embedded blocks using HE and Congo Red.

Selected formalin-fixed sections were immunostained with antibodies

against phosphorylated neurofilaments (SMI-31; Covance, Emeryville, CA; 1:500),

amyloid β protein (4G8; Covance; 1:5000), ubiquitin (Dako, Glöstrup, Denmark;

1:8000), macrophages (CD68; Dako; 1:100), T lymphocytes (CD3; Dako; 1:20), B

lymphocytes (CD20; Dako; 1:50), helper T lymphocytes (CD4; Dako; 1:400), and

cytotoxic T lymphocytes (CD8; Dako; 1:20) using appropriate antigen retrieval

methods.   Immunohistochemistry using antibodies against human leukocyte antigen-I

(HLA-I; Dako; 1:200) and HLA-II (Dako, 1:100) was performed on frozen sections.

The EnVision system (Dako) was used for these immunolabeling studies. Peroxidase

labeling was visualized with diaminobenzidine as the chromogen.

Granulomas were defined as collections of inflammatory cells in which

more than 60% of the inflammatory cells were macrophages or epithelioid histiocytic

cells, as judged by HE or specific macrophage marker staining (CD68). The presence

of Langerhans-type or histiocytic giant cells was unnecessary to be judged as

granulomas [9]. We paid special attention to exclude necrotic regions to avoid

including caseating granulomas [9].

2.3 Case classification

With reference to the pathological features of IBM (endomysial inflammatory

infiltrates; rimmed vacuoles; protein accumulation; and upregulation of HLA class I

around muscle fibers), we made a clinicopathological diagnosis of IBM [6]. Patients

who demonstrated only these features were designated as typical IBM without

granuloma group. Patients showing granuloma formation in addition to typical IBM

clinicopathologic characteristics were categorized into the IBM with granuloma

group.

2.4 Statistical analysis

Differences in age at disease onset and in the results of laboratory tests between the

typical IBM without granuloma group and the IBM with granuloma group were

assessed using a Mann-Whitney *U* test. Sex, diagnosis classification of IBM, initial

weakness, and pathological findings were assessed using chi-square test and Fisher's

exact probability test. Statistical significance was defined as $p < 0.05$. Statistical

analyses were performed using SPSS version 22 (IBM, Armonk, NY).

3. Results

3.1 Clinical profiles

A total of 307 patients with myopathy were analyzed in our department during the

study period. Fifteen patients satisfied the clinical diagnostic criteria of IBM [6]. Five

patients were categorized as clinicopathologically defined IBM. Four and 6 patients

were categorized as clinically defined IBM and probable IBM, respectively.

Granuloma formation in muscle tissues was noted in 4 patients. In these patients, one

patient met the criteria for clinicopathologically defined IBM, whereas 2 and 1

patients were categorized as clinically defined IBM and probable IBM, respectively.

Regarding IBM patients with granuloma, clinical features are summarized

in Table 1. One patient (patient 4) experienced dysphagia. One patient (patient 3)

showed lymphadenopathy with non-caseating granulomas in the mandibular region

and mediastinum; however, clinical features suggesting sarcoidosis, such as bilateral

hilar lymphadenopathy on chest radiography, erythema nodosum, uveitis, and

maculopapular skin lesions, were absent. Other patients had none of the above clinical

or laboratory findings considered suggestive of sarcoidosis. Several simultaneous

diseases were observed in patients 2, 3 and 4 including hematological diseases and

autoimmune disorders. Patient 2 received a diagnosis of Sjögren syndrome and

myelodysplastic syndrome. Diagnosis of thyroiditis was given in patients 3 and 4.

Patient 3 have also suffered from interstitial pneumonitis. All patients received several

immunomodulating treatments, including oral prednisone, methylpredonisolone pulse

therapy, IVIg, and oral administration of tacrolimus. No improvements were observed

after the treatments.

A comparison of clinical manifestations and laboratory findings between the typical IBM without granuloma group and IBM with granuloma group are summarized in Table 2. There were no significant differences regarding the clinical profile between these groups. Several patients in the typical IBM without granuloma group were also positive for anti-nuclear antibody, anti-mitochondrial antibody, anti Ro/SS-A antibody, and exhibited a combined infection with hepatitis B virus and hepatitis C virus. Although patients with typical IBM received immunomodulating treatments, such as oral prednisone, IVIg, and immunosuppressants, all patients showed progression of muscular weakness regardless of the treatments administered. Additionally, 2 patients were observed but were not treated apart from physical rehabilitation and exhibited slowly progressive muscular weakness.

3.2 Pathological findings

The quadriceps femoris muscle was the most frequently biopsied muscle in this series; however, 3 patients underwent a biopsy of the biceps brachii muscle. The tibialis anterior muscle and semimembranous muscle were selected in 3 patients.

All patients demonstrated pathological features typical of IBM, including

many necrotic and regenerating fibers alongside CD8-positive T lymphocytes,

mononuclear cell infiltration, a variable amount of rimmed vacuoles, positive HLA-I

expression and protein accumulation in vacuoles (Figs 1A-C; Table 3). Several cases

demonstrated small amount of COX-deficient fibers. In addition to theses typical

structures as IBM, several granulomas were detected in the muscle tissues of the IBM

with granuloma group (Figs 1A, D, E, 2A). The granulomas comprised a mixture of

inflammatory cells, such as epithelioid histiocytic cells surrounded by lymphocytes.

These epithelioid cells showed macrophage-like features and were CD68 positive

(Figs 2A-C). No apparent multinucleated cells were observed in any patient. Most of

the lymphocytes around epithelioid cells were CD4-positive cells consistent with

typical granulomas (Figs 2C-F) [10]. As regards the myopathological findings except

for the presence of granuloma, there were no significant differences between the two

groups (Table 3).

4. Discussion

We identified IBM with granuloma formation in the muscle tissues of 4 (27%) of 15

consecutive patients who underwent muscle examinations. All patients met current

clinocopathological diagnostic criteria for IBM [6, 11]. Although mediastinal lymph

node granulomas were histologically demonstrated in patient 3, other patients

demonstrated granuloma formation confined to muscle tissues as determined by

intensive examinations. Hence, no patients received a diagnosis of sarcoidosis

because of inadequate evidence.

Granulomas are structures associated with reaction to a foreign

environment [2]. There are several reports of patients with GM showing the following

features: myositis with granuloma, no evidence of sarcoidosis, and a good response to

immunotherapy [2, 9]. Somewhat interestingly, some GM patients mimicked IBM in

clinical characteristics; however, these cases showed no pathological features

consistent with IBM, such as rimmed vacuole, amyloid deposition or abnormal protein

accumulation in muscle fiber [12]. In a large muscle biopsy series, 12 cases (0.4%) of

2985 specimens were identified as having granulomatous inflammation [8]. It is well

known that some patients with sarcoidosis demonstrate asymptomatic granuloma

formation in muscle; however, microscopic criteria for the differentiation of sarcoid

lesions from other granulomatous myopathies are still lacking[10]. The relationship

between GM and the limited lesions of sarcoidosis in muscle remains unknown.

It is uncertain whether granuloma formation in patients with the typical

clinicopathologic characteristics of IBM is a coincidence or not. There are several

case reports showing a combination of sarcoidosis and IBM [3, 5]. Clinical

manifestations related to sarcoidosis preceded IBM in all reported cases. The authors

of the above mentioned cases assumed that sarcoidosis was responsible for inducing

IBM under uncertain circumstances [3, 5]. We presume that IBM and granuloma

might share a similar pathogenesis on account of the following reasons. Firstly, our

cases of IBM with granuloma formation were indistinguishable from typical IBM in

terms of the clinicopathologic profiles, including clinical manifestations, pathological

findings, and an unfavorable response to therapy (Tables 2 and 3), suggesting that IBM

with granuloma could be a form of IBM. Secondly, inflammatory and degenerative

mechanisms in IBM closely interrelate with each other [13]. A mouse model of IBM

showing augmenting amyloid β protein in skeletal muscle demonstrated inclusion

bodies and inflammatory infiltrates [14]. Abnormal protein accumulation in muscle

fiber is a typical pathological feature of IBM patients. Deposited proteins

acknowledged as foreign bodies against immune systems might develop granuloma

formation. Finally, IBM and granuloma could share the same pathomechanistic

background. Sarcoidosis and IBM are Th1-mediated immune diseases [7, 15].

Toll-like receptors (TLRs) are pattern-recognition receptors of the innate immune

system that recognize conserved microbial motifs [16], and are involved in autophagy

[17]. Mechanisms involving autophagy dysregulation are observed in IBM [18].

TLRs are also associated with inflammation in idiopathic inflammatory myopathies

including IBM [16, 18]. Toll-like receptor 2 (TLR2), a member of the TLR family, is

associated with activation of granulomatous inflammation in sarcoidosis [19].

Furthermore, autophagy-related genes may contribute to granuloma formation [20].

In conclusion, we established a new form of IBM showing granuloma

formation. Our results suggest that IBM with granuloma is identical to typical IBM in

terms of the clinicopathological profile and an unfavorable response to

immunomodulating therapies. We presume that IBM and granuloma formation could

share similar pathomechanisms in terms of autophagy dysregulation. Further cases are

necessary to clarify in detail the significance of granulomas in patients with IBM.

(2,074 words)

Acknowledgements

References

1. Mikol J, Engel AG. Inclusion body myositis, in: Engel AG, Franzini-Armstrong C

   (Eds.), Myology, 3rd ed., McGraw-Hill, New York, 2004, pp. 1367–88.

2. Prieto-González S, Grau JM. Diagnosis and classification of granulomatous

   myositis. Autoimmun Rev 2014;13:372–4.

3. Danon MJ, Perurena OH, Ronan S, et al. Inclusion body myositis associated with

   systemic sarcoidosis. Can J Neurol Sci 1986;13:334–6.

4. Mhiri C, Gherardi R. Inclusion body myositis in French patients. A

   clinicopathological evaluation. Neuropathol App Neurobiol 1990;16:333–44.

5. Vattemi G, Tonin P, Marini M, et al. Sarcoidosis and inclusion body myositis.

   Rheumatology 2008;28:1433–5.

6. Rose MR, ENMC IBM Working Group. 188th ENMC international workshop:

   inclusion body myositis, 2–4 December 2011, Naarden, the Netherlands.

   Neuromuscul Disord 2013;23:1044–55.

7. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014;383:1155–67.

8. Prayson RA. Granulomatous myositis. Clinicopathologic study of 12 cases. Am J

   Clin Pathol 1999;112:63–8.

9. Le Roux K, Streichenberger N, Vial C, et al. Granulomatous myositis: a clinical

    study of thirteen cases. Muscle Nerve 2007;35:171–7.

10. Banker BQ, Engel AG. Other inflammatory myopathies. in: Engel AG,

    Franzini-Armstrong C (Eds.), Myology, 3rd ed., McGraw-Hill, New York, 2004,

    pp. 1445–72.

11. Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of

    diagnostic criteria for inclusion body myositis. Neurology 2014;83:426-33.

12. Larue S, Maisonobe T, Benveniste O, et al. Distal muscle involvement in

    granulomatous myositis can mimic inclusion body myositis. J Neurol Neurosurg

    Psychiatry 2011;82:674–7.

13. Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BGM.

    Amyloid deposits and inflammatory infiltrates in sporadic inclusion body

    myositis: the inflammatory egg comes before the degenerative chicken. Acta

    Neuropathol 2015;129:611–24.

14. Kitagawa M, Green KM, Caccamo A, LaFerla FM. Genetically augmenting Aβ42

    levels in skeletal muscle exacerbates inclusion body myositis-like pathology and

    motor deficits in transgenic mice. Am J Pathol 2006;168:1986–97.

15. De Paepe B, De Keyzer K, Martin J, et al. Alpha-chemokine receptors CXCR1–3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol 2005;109:576–82.

16. Brunn A, Zornbac K, Hans VH, et al. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 2012;71:855–67.

17. Delgado MA, Elmaoued RA, Davis AS, et al. Toll-like receptors control autophagy. EMBO J 2008;27:1110–21.

18. Cappelletti C, Galbardi B, Kapetis D, et al. Autophagy, inflammation and innate immunity in inflammatory myopathies. PloS One 2014;9:e111490.

19. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010;181:360–73.

20. Brinar M, Vermeire S, Cleynen I, et al. Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients. J Crohns Colitis 2012;6:43–50.

Figure captions

Figure 1. Muscle biopsy findings in patients with inclusion body myositis (IBM) with granuloma. Severe myopathic changes showing variations in fiber size, and infiltration of adipose tissue with granuloma formation (A). Typical myopathologic features of IBM, including mononuclear cell infiltration in the endomysium with scattered rimmed vacuoles (B, C). Granulomas comprising epithelioid cells surrounded by lymphocytes in the endomysium (D, E). A from patient 1; B-D from patient 2; E from patient 4. A, D, E hematoxylin and eosin stain; B, C modified Gomori-trichrome stain. Bars 100 μm for A, 50 μm for B-E.

Figure 2. Immunohistochemical profiles of the granuloma in patient 3. Granuloma formation (A) was observed in muscle tissue comprising CD68-positive epithelioid cells (B), CD3- (C) and CD4-positive (D) T lymphocytes. CD8-positive T lymphocytes were less numerous than CD4-positive cells (E). Few CD20-positive B lymphocytes were identified (F). A hematoxylin and eosin stain. Bars = 100 μm.

Table 1. Profiles of patients with inclusion body myositis with granuloma formation

	Patient 1	Patient 2	Patient 3	Patient 4
Age (onset; years)	51	59	56	67
Sex	Female	Male	Male	Female
Diagnosis classification	Clinically defined	Probable	Clinicopathologically defined	Clinically defined
Duration until diagnosis (months)	72	30	192	28
Granulomas in other organs	None	None	Lymph nodes	None
Laboratory results				
CK (IU/L)	1765	385	1447	246
LDH (IU/L)	575	294	582	244
Aldolase (IU/L)	16	N.E.	22	6
Myoglobin (ng/ml)	N.E.	464.7	300	139.1
CRP (mg/dl)	0	0.2	0.2	0
ESR (mm; 1 hour)	16	25	12	31
Other disorders	None	Sjögren syndrome, MDS	IP, thyroiditis	Thyroiditis
Therapy	Corticosteroids	Corticosteroids	Corticosteroids, IVIg, TAC	Corticosteroids, TAC
Response	No	No	No	No

CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IP,

interstitial pneumonitis; IVIg, intravenous immunoglobulin; LDH, lactate

dehydrogenase ; MDS, myelodysplastic syndrome; N.E., not examined; TAC,

tacrolimus

Table 2. Clinical features of patients with inclusion body myositis (IBM) with and without granuloma formation

	Total	Typical IBM without granuloma	IBM with granuloma	p value[*]
	n = 15	n = 11	n = 4	
Age at diagnosis (median years with range)	62 (51–84)	70 (51–84)	58 (51–67)	$p = 0.169$
Male/female	9/6	7/4	2/2	$p = 0.538$
Diagnosis classification of IBM				
Clinicopathologically defined	5	4	1	$p = 0.464$
Clinically defined	4	2	2	
Probable	6	5	1	
Initial weakness				
Oral	0	0	0	$p = 0.637$
Arm	3	2	1	
Leg	12	9	3	
Duration until diagnosis (median months with range)	48 (12–192)	48 (12–84)	51 (28–192)	$p = 0.395$
Laboratory results (median with range)				
CK (IU/L)	491 (186–1765)	491 (186–1469)	916 (246–1765)	$p = 0.601$

	Total	Typical IBM without granuloma	IBM with granuloma	p value[*]
LDH (IU/L)	288 (166–582)	279 (166–370)	435 (244-582)	$p = 0.192$
Aldolase (IU/L)	10 (3–22)	9 (3–17)	16 (6–22)	$p = 0.309$
Myoglobin (ng/ml)	360 (67–563)	419 (67–563)	300 (139-465)	$p = 0.732$
CRP (mg/dl)	0.14 (0–0.6)	0.14 (0.01–0.6)	0.1 (0-0.2)	$p = 0.390$
ESR (mm/hour)	25 (12–64)	25 (13–64)	21 (12-31)	$p = 0.286$

IBM, inclusion body myositis; CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase

* p value was assessed between the typical IBM group and the IBM with granuloma group.

Table 3. Pathological features of the muscles of patients with inclusion body myositis

(IBM) with and without granuloma formation

	Total	Typical IBM without granuloma	IBM with granuloma	
	n = 15	n = 11	n = 4	p value[*]
Biopsied muscle	Biceps brachialis 3 Quadriceps 8 Tibialis anterior 2 Semimembranous 1	Biceps brachialis 2 Quadriceps 6 Tibialis anterior 2	Biceps brachialis 1 Quadriceps 2 Semimembranous 1	
Inflammatory cell infiltration	11/15	7/11	4/4	p = 0.242
Rimmed vacuole	15/15	11/11	4/4	–[†]
Congo Red-positive structures	1/15	0/11	1/4	p = 0.267
COX-deficient fibers	5/15	4/11	1/4	p = 0.593
Aβ-positive inclusions[‡]	6/13	4/10	2/3	p = 0.437
Ubiquitin-positive inclusions[‡]	10/13	8/10	2/3	p = 0.580
HLA-I positive	13/15	9/11	4/4	p = 0.524
HLA-II positive	5/15	3/11	2/4	p = 0.459

Aβ, amyloid β protein; COX, cytochrome C oxidase; HLA, human leukocyte antigen;

IBM, inclusion body myositis

* *p* value was assessed between the typical IBM group and the IBM with granuloma

group.

† *p* value was not able to be calculated.

‡ Paraffin-embedded sections were unavailable for one case in both groups.